Tim Godel1, Anja Köhn2, Nicole Muschol2, Moritz Kronlage3, Daniel Schwarz3, Jennifer Kollmer3, Sabine Heiland3, Martin Bendszus3, Victor-Felix Mautner4, Philipp Bäumer3,5. 1. Department of Neuroradiology, Neurological University Clinic, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Tim.godel@med.uni-heidelberg.de. 2. Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. 3. Department of Neuroradiology, Neurological University Clinic, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. 4. Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. 5. Department of Radiology, German Cancer Research Institute, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Abstract
PURPOSE: To examine dorsal root ganglia and the proximal nerve segments in female patients with Fabry disease by functional and morphometric magnetic resonance neurography. METHODS: In this prospective multicenter study the lumbosacral dorsal root ganglia and proximal sciatic nerve were examined in ten female patients with Fabry disease by a standardized magnetic resonance neurography protocol at 3 T. Volumes of dorsal root ganglia L3-S2, permeability of dorsal root ganglia L5 and S1 and the spinal nerve L5 as well as the cross-sectional area of the proximal sciatic nerve were compared to 16 gender-matched healthy controls. RESULTS: Dorsal root ganglia were symmetrically enlarged by 54% (L3), 79% (L4), 60% (L5), 94% (S1), and 106% (S2) (p < 0.001). Additionally, permeability of the blood-tissue interface was decreased by 47% (p < 0.001). This finding was most pronounced in the peripheral zone of the dorsal root ganglia, where the cell bodies of the primary sensory neurons are located (p < 0.001). While spinal nerve permeability showed no differences compared to healthy controls, proximal sciatic nerve cross-sectional area was mildly increased by 6% (p < 0.01). CONCLUSION: Although heterozygous, Fabry females show severe enlarged dorsal root ganglia with a concomitant dysfunctional perfusion, even in patients with minor disease progression and in patients who are not considered for enzyme replacement therapy yet. Alterations in dorsal root ganglia volume and perfusion might serve as a very early in vivo marker for involvement of the peripheral nervous system in Fabry disease, even in patients with residual enzyme activity.
PURPOSE: To examine dorsal root ganglia and the proximal nerve segments in female patients with Fabry disease by functional and morphometric magnetic resonance neurography. METHODS: In this prospective multicenter study the lumbosacral dorsal root ganglia and proximal sciatic nerve were examined in ten female patients with Fabry disease by a standardized magnetic resonance neurography protocol at 3 T. Volumes of dorsal root ganglia L3-S2, permeability of dorsal root ganglia L5 and S1 and the spinal nerve L5 as well as the cross-sectional area of the proximal sciatic nerve were compared to 16 gender-matched healthy controls. RESULTS: Dorsal root ganglia were symmetrically enlarged by 54% (L3), 79% (L4), 60% (L5), 94% (S1), and 106% (S2) (p < 0.001). Additionally, permeability of the blood-tissue interface was decreased by 47% (p < 0.001). This finding was most pronounced in the peripheral zone of the dorsal root ganglia, where the cell bodies of the primary sensory neurons are located (p < 0.001). While spinal nerve permeability showed no differences compared to healthy controls, proximal sciatic nerve cross-sectional area was mildly increased by 6% (p < 0.01). CONCLUSION: Although heterozygous, Fabry females show severe enlarged dorsal root ganglia with a concomitant dysfunctional perfusion, even in patients with minor disease progression and in patients who are not considered for enzyme replacement therapy yet. Alterations in dorsal root ganglia volume and perfusion might serve as a very early in vivo marker for involvement of the peripheral nervous system in Fabry disease, even in patients with residual enzyme activity.
Authors: Derralynn A Hughes; Miguel-Ángel Barba Romero; Carla E M Hollak; Roberto Giugliani; Patrick B Deegan Journal: Mol Genet Metab Date: 2011-03-31 Impact factor: 4.797
Authors: C Whybra; C Kampmann; F Krummenauer; M Ries; E Mengel; E Miebach; F Baehner; K Kim; M Bajbouj; A Schwarting; A Gal; M Beck Journal: Clin Genet Date: 2004-04 Impact factor: 4.438
Authors: C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi Journal: J Inherit Metab Dis Date: 2007-03-08 Impact factor: 4.750
Authors: Dominique P Germain; Joel Charrow; Robert J Desnick; Nathalie Guffon; Judy Kempf; Robin H Lachmann; Roberta Lemay; Gabor E Linthorst; Seymour Packman; C Ronald Scott; Stephen Waldek; David G Warnock; Neal J Weinreb; William R Wilcox Journal: J Med Genet Date: 2015-03-20 Impact factor: 6.318
Authors: Moritz Kronlage; Thomas David Fischer; Rouven Behnisch; Daniel Schwarz; Philipp Bäumer; Veronique Schwehr; Sabine Heiland; Martin Bendszus; Tim Godel Journal: Diagnostics (Basel) Date: 2022-06-28